Product Value—GORE® SYNECOR Biomaterials

Quality outcomes start with quality materials

Image of GORE® SYNECOR BiomaterialsThe GORE® SYNECOR Biomaterials offer permanent strength with rapid* tissue ingrowth to promote healing and are designed to minimize complications in the repair of hernias and abdominal wall soft tissue deficiencies.

 

Projected costs for hernia repair in the U.S.

$20 billion annual cost of hernia repair in the US

  

Typical ventral hernia mesh spend for U.S. hospitals 20194

8 percent of units equals 45 percent of total spend

 

Reducing Recurrence Rate

Data indicates the risk of hernia recurrence is a leading factor for physicians in choosing a mesh;* risk of complications and comorbid conditions are some of the patient characteristics that drive this choice. 

Ventral hernia repairs (VHRs) continue to rise in incidence and cost. By reducing recurrence rate alone, a cost savings of the U.S. $32 million dollars for each 1% reduction in operations would result.5

$32 million in cost savings for each 1% reduction in operations

GORE® SYNECOR Biomaterial is less than half the cost of leading biologics and the cost is favorable compared to other biosynthetics.6 Based on patient selection criteria, clinicians may utilize GORE® SYNECOR Biomaterial as an alternative.

Compared to biologics, GORE® SYNECOR Biomaterials offer permanent strength that may lead to fewer hernia recurrences and better quality outcomes by:

  • Enabling single-stage durable repair for challenging hernia cases, and may reduce overall cost.
  • Lowering costs to use compared to biologic and long-term resorbable products of similar size.6
  • Lightweight mesh clinical studies demonstrating a potential for reduced re-interventions and fewer complications for complex, high-risk hernia repair.7,8
  • Allowing for a single surgery with potential for faster recovery and fewer complications versus a staged-repair requiring multiple surgeries.


 

product image

GORE® SYNECOR Biomaterial full product information

Learn more >

the future of value analysis

NEW - Value Analysis Handbook

Views from thought leaders on the future of value analysis

Three people discussing documents

Want more information?

Connect with one of our Corporate Account Directors to learn more about the value Gore can deliver to your healthcare institution.

 

Contact us >

INDICATIONS FOR USE: The GORE® SYNECOR Intraperitoneal Biomaterial is intended for use in the repair of hernias and abdominal wall or thoracic wall soft tissue deficiencies that may require the addition of non-absorbable reinforcing or bridging material.

CONTRAINDICATIONS: Not for reconstruction of cardiovascular defects.

INDICATIONS FOR USE: The GORE® SYNECOR Preperitoneal Biomaterial is intended for use in the repair of hernias and abdominal wall soft tissue deficiencies that may require the addition of a non-absorbable reinforcing or bridging material.

CONTRAINDICATIONS: Not for reconstruction of cardiovascular defects.

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

eIFU Symbol

* Data on file 2015; W. L. Gore & Associates, Inc; Flagstaff, AZ.

  1. Luijendijk RW, Hop WC, van den Tol MP, et al. A comparison of suture repair with mesh repair for incisional hernia. New England Journal of Medicine 2000;343(6):392-398.
  2. Saleh S, Plymale MA, Davenport DL, Roth JS. Risk-assessment score and patient optimization as cost predictors for ventral hernia repair. Journal of the American College of Surgeons 2018;226(4):540-546.
  3. Fischer JP, Basta MN, Mirzabeigi MN, et al. A risk model and cost analysis of incisional hernia after elective abdominal surgery based on 12,373 cases. the case for targeted prophylactic intervention. Annals of Surgery 2016;263(5):1010-1017.
  4. © 2022 Millennium Research Group, Inc. All rights reserved. Reproduction, distribution, transmission or publication is prohibited. Reprinted with permission.
  5. Poulose BK, Shelton J, Phillips S, et al. Epidemiology and cost of ventral hernia repair: making the case for hernia research. Hernia 2012;16(2):179-183.
  6. Nisiewicz MJ, Plymale MA, Davenport DL, et al. Validation and extension of the ventral hernia repair cost prediction model. Journal of Surgical Research 2019;244:153-159.
  7. Carbonell A, Cobb W, Doerhoff C, et al. Clinical Quality Improvement (CQI): a post market method to evaluate a new mesh for ventral/incisional hernia repair. Presented at the Abdominal Wall Reconstruction Conference; June 8-10, 2017; Washington, D.C.
  8. Grimsley L, Forman B, Carbonell A, et al. Evaluating the real world use of a new hybrid hernia mesh. Presented at the 2018 International Hernia Congress, March 12-15, 2018, Miami, FL. Hernia 2018;22(1)Supplement:S178. P-1316.

22455252-EN

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.